NCT06623396 - A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions

Mesothelin PositiveMesothelin-Expressing TumorsEsophageal AdenocarcinomaEsophageal AdenocarcinomasEsophagogastric AdenocarcinomaPeritoneal CarcinomatosisBreast NeoplasmsDiabetes Mellitus

Interventions

BIOLOGICAL

M28z1XXPD1DNR CAR

Participants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER